Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

Trial Identifier: 3475-913
Sponsor: MSD
Start Date: February 2019
Primary Completion Date: February 2022
Study Completion Date: February 2024
Condition: Skin Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Results Plain Language Summary - EMEA Swedish
Results Plain Language Summary - EMEA Italian
Results Plain Language Summary - English
Results Plain Language Summary - EMEA Spanish
Results Plain Language Summary - NA Canadian French
Results Plain Language Summary - EMEA French

Trial Locations

Country Location
Australia, New South Wales North Sydney, New South Wales, Australia, 2065
Australia, New South Wales Waratah, New South Wales, Australia, 2298
Canada, NB Moncton, NB, Canada, E1C 6Z8
Canada, ON Toronto, ON, Canada, M5G 2M9
France, Calvados Caen, Calvados, France, 14033
France, Gironde Bordeaux, Gironde, France, 33000
France, Hauts-de-Seine Boulogne-Billancourt, Hauts-de-Seine, France, 92100
France, Indre-et-Loire Chambray Les Tours, Indre-et-Loire, France, 37170
France, Nord Lille, Nord, France, 59037
Italy, Milano Milano, Italy, 20141
Italy, Napoli Napoli, Italy, 80131
Italy, Padova Padova, Italy, 35128
Italy, Toscana Siena, Toscana, Italy, 53100
New Zealand, Auckland Auckland, New Zealand, 1023
Spain, Barcelona Barcelona, Spain, 08036
Spain, Barcelona Barcelona, Spain, 08035
Spain, Madrid Madrid, Spain, 28046
Spain, Valenciana, Comunitat Valencia, Valenciana, Comunitat, Spain, 46014
Sweden, Stockholms lan Solna, Stockholms lan, Sweden, 171 64
Sweden, Vastra Gotalands lan Goeteborg, Vastra Gotalands lan, Sweden, 413 45
United States, NY New York, NY, United States, 10016
United States, NY New York, NY, United States, 10029